Breaking Down Shanghai RAAS Blood Products Co., Ltd. Financial Health: Key Insights for Investors

Peel back the curtain on Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) with a fact-packed snapshot that every investor should know: Q3 2025 revenue hit ¥2.14 billion (up 3.72% YoY) while year-to-date sales slipped to ¥6.09 billion (down 3.54%), TTM revenue stood at ¥7.95 billion (down 4.67%) against a 2024 full-year of ¥8.18 billion, and market cap sits near ¥43.79 billion with a P/S of 5.51; profitability shows a Q3 net attributable profit of ¥441 million (down 26.16%) and YTD net profit of ¥1.47 billion (down 19.97%), TTM diluted EPS ¥0.29 (P/E 14.06), ROE 5.73% and ROIC 3.36% despite a gross/operating margin around 28.83% and operating income erosion from ¥2.26 billion to ¥1.74 billion; balance sheet and liquidity readings are strong-debt/equity just 0.09, total debt ≈¥94 million, cash ≈¥2.98 billion, current ratio 3.37 and quick ratio 1.74-offset by a 43.54% drop in cash & equivalents to ¥2.096 billion and a receivables balance of ¥2.904 billion (turnover 2.37); valuation and cash-flow flags include EV/EBITDA 21.45, EV/FCF of -72.55, PEG 3.48 and declining revenue-per-share growth of -6.80% over 12 months; governance and strategic risks-termination of the Haier Biotech restructuring, Grifols' 20% stake sale for $1.8 billion-and growth moves like the planned ¥4.2 billion Nanyue Biological acquisition and plasma-network expansion create a volatile mix worth digging into further-read on for the full financial breakdown and what these numbers mean for investors.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Revenue Analysis

• Q3 2025 revenue: ¥2.14 billion (+3.72% YoY)
• Year-to-date (through Q3 2025) revenue: ¥6.09 billion (-3.54% YoY)
• TTM revenue as of June 2025: ¥7.95 billion (-4.67% YoY)
• Full-year 2024 revenue: ¥8.18 billion (+2.67% YoY)
• Revenue per employee: ≈ ¥2.37 million (3,350 employees)
• Market capitalization: ≈ ¥43.79 billion; P/S ratio: 5.51
• Revenue per share: 12‑month trend average growth ≈ -6.80% per year

• Interpretation: Q3 strength did not offset earlier weakness-TTM and YTD declines indicate pressure across recent quarters despite a positive Q3 quarter-on-quarter signal.
• Productivity & scale: revenue/employee (~¥2.37M) and workforce size (3,350) frame operational leverage; investors should compare against peers in plasma-derived biologics for context.
• Valuation note: P/S of 5.51 with shrinking TTM revenue implies the market is pricing either strong margin/ROE expectations or standalone resilience in cash flows despite top-line softness.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Profitability Metrics

• Q3 2025 net profit attributable to shareholders: ¥441 million (down 26.16% YoY).
• Year-to-date (as of Q3 2025) net profit: ¥1.47 billion (down 19.97% YoY).
• Trailing twelve months (TTM) operating income (ending Mar 2025): ¥2.145 billion; operating margin: 28.83%.
• Gross margin: 28.83% (operating income for the period: ¥1.74 billion, down from ¥2.26 billion the previous year).
• Diluted EPS (TTM ending Jun 2025): ¥0.29; P/E ratio: 14.06.
• Return on equity (ROE): 5.73%; Return on invested capital (ROIC): 3.36%.

• Margin profile: Gross and operating margins at ~28.8% indicate solid unit economics despite lower absolute profits.
• Profit trend risk: Double-digit declines in quarterly and YTD net profit highlight near-term pressure on earnings.
• Capital efficiency: ROE of 5.73% and ROIC of 3.36% point to modest returns relative to cost of capital expectations.
• Valuation: P/E of 14.06 on diluted EPS of ¥0.29 places current market pricing in a moderate range vs. peers (requires peer comparison for context).

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Debt vs. Equity Structure

Shanghai RAAS Blood Products Co., Ltd. displays a conservative capital structure characterized by very low external debt, strong liquidity and high interest coverage. Key metrics as of March 2025 indicate limited leverage and ample short-term operating cushion.

• Debt-to-equity ratio: 0.09 - very low debt relative to shareholders' equity.
• Debt-to-EBITDA (leverage ratio): 1.48 - moderate leverage, manageable given earnings.
• Interest coverage ratio: 76.35 - extremely strong ability to service interest expense.
• Current ratio: 3.37 - strong short-term liquidity.
• Quick ratio: 1.74 - solid near-cash liquidity excluding inventories.
• Cash position: ≈ ¥2.98 billion - substantial liquidity buffer.
• Total debt: ≈ ¥94 million - minimal absolute debt load.

For context on corporate background and how the business generates cash that supports this balance-sheet profile, see: Shanghai RAAS Blood Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Liquidity and Solvency

Key short-term liquidity and long-term solvency indicators for Shanghai RAAS Blood Products show a mixed picture: strong coverage and liquidity ratios alongside concentrated working capital in receivables and a multi-year compression of operating margin.

• Operating cash flow (Q3 2025): ¥691 million - +33.99% YoY.
• Cash & cash equivalents (Sept 2025): ¥2.096 billion - down 43.54% YoY.
• Accounts receivable: ¥2.904 billion; receivables turnover ratio: 2.37.
• Current ratio: 3.37; Quick ratio: 1.74.
• Interest coverage ratio: 76.35.
• Operating margin: 5-year declining trend, averaging -6.70% annual decrease.

• Strengths: ample liquidity buffers (current ratio 3.37; quick ratio 1.74) and extremely high interest coverage (76.35) reduce insolvency risk.
• Risks: sharp drop in cash balances (¥2.096B, -43.54% YoY) and heavy receivables (¥2.904B) with turnover of 2.37 concentrate funding risk and working-capital exposure.
• Structural concern: persistent deterioration in operating margin (≈ -6.70% p.a. over five years) may erode cash generation if not reversed despite recent OCF improvement.

Related background and corporate context: Shanghai RAAS Blood Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Valuation Analysis

• Book-based valuation: P/B of 1.31 suggests modest premium to accounting equity; P/TBV 1.81 warns intangibles meaningfully affect book coverage.
• Profitability multiples: EV/EBITDA 21.45 and EV/EBIT 24.21 are high for a business with recent revenue contraction, implying stretched market expectations for margin expansion or recovery.
• Cash flow concerns: EV/FCF at -72.55 signals negative free cash flow - investors should probe drivers (working capital, capex, one-offs).
• Growth-adjusted price: PEG of 3.48 implies the share price is expensive relative to forecast earnings growth, especially given a -6.8% revenue-per-share trend.
• Revenue efficiency: P/S of 5.51 combined with declining revenue per share increases sensitivity to margin or volume headwinds.

• Valuation sensitivity points to monitor:
  • Reversal or continuation of revenue-per-share decline.
  • Trajectory of free cash flow and capital spending.
  • Realized margin improvement to justify EV/EBITDA and EV/EBIT multiples.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Risk Factors

• Strategic disruption: Termination of the major asset restructuring plan with Haier Biotech in January 2025 removes a planned growth/vertical-integration pathway and creates short- to medium-term uncertainty around alternative M&A or partnership strategies.
• Shareholder base shift: Grifols' divestiture of its ~20% stake in 2024 for approximately $1.8 billion may change governance dynamics, reduce a strategic investor's influence, and increase share volatility if new owners pursue active portfolio changes.
• Profitability deterioration: Operating margin has been deteriorating over five years, averaging a -6.70% annual decline, signaling persistent margin pressure from costs, pricing, or product mix.
• Revenue erosion per share: Revenue per share has trended downward over the past 12 months, with an average rate of change around -6.80% per year, implying potential demand weakness or dilution outsizing top-line growth.
• Cash-flow stress: The company exhibits a negative EV/FCF ratio of -72.55, consistent with negative free cash flow and constraints on internally funded growth, dividends, or buybacks.
• Valuation concern: A PEG ratio of 3.48 suggests the stock may be priced richly relative to expected earnings growth, increasing downside risk if growth slows or misses expectations.
• Execution and financing risk: Negative FCF and margin declines elevate refinancing and capital-allocation risk - new projects or resumed M&A (post-Haier cancellation) may require equity issuance or costly debt.
• Market and regulatory exposure: As a plasma-derived products company, RAAS remains exposed to regulatory approvals, plasma supply variability, and pricing/ reimbursement pressures across markets.

• Near-term investor considerations: monitor cash burn, funding sources, new strategic initiatives after the Haier cancellation, and any follow-up disclosures about the use of proceeds or reinvestment of capital from Grifols' exit.
• Quantitative red flags to watch: consecutive quarters of negative FCF, further declines in operating margin, continued negative revenue-per-share trends, and a falling share of institutional holders willing to support long-term strategy.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Growth Opportunities

• Planned acquisition of Nanyue Biological for ¥4.2 billion aimed at materially increasing plasma collection capacity and accelerating scale.
• Vertically integrated business model covering plasma collection, fractionation, manufacturing and distribution - enabling margin capture and supply-chain control.
• Focused investment to expand plasma collection network (new centers and donor recruitment programs) to secure raw material supply and reduce unit costs.
• Product pipeline expansion targeting both traditional plasma-derived therapies and higher-value specialty biologics to diversify revenue streams.
• Export growth into Southeast Asia and Latin America, providing non-domestic revenue avenues and mitigating single-market concentration risk.

• Financial flexibility: ~¥2.98 billion in cash provides runway to complete the ¥4.2 billion acquisition (potentially supplemented by financing) and to fund network expansion.
• Valuation context: Market cap ≈ ¥43.79 billion with P/S of 5.51 suggests investor expectations of sustained revenue growth; successful integration of Nanyue would support upward re-rating.
• International diversification: Existing exports to Southeast Asia and Latin America can be scaled through regulatory approvals and local partnerships, increasing addressable market and FX-denominated revenues.
• Operational synergies: Vertical integration and increased plasma throughput from the acquisition should improve gross margins and utilization of fractionation capacity.